Volume 22, Number 8—August 2016
Research
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria
Table
Baseline characteristics and follow-up laboratory data for patients with uncomplicated Plasmodium falciparum malaria who were given ACT*
Characteristic | All, n = 20 | Without posttreatment hemolysis, n = 12 | With posttreatment hemolysis, n = 8 | p value | With compensated posttreatment hemolysis, n = 4 | With uncompensated posttreatment hemolysis, n = 4 | p value |
---|---|---|---|---|---|---|---|
Baseline | |||||||
Age, y | 35 (26–40) | 31 (17–40) | 38 (30–43) | 0.18 | 32 (22–42) | 40 (27–46) | 0.15 |
Children | 3/20 (15.0) | 3/12 (25.0) | 0/8 (0) | 0.24 | 0/4 (0) | 0 (0) | |
African ethnicity | 13/20 (65.0) | 9/12 (75.0) | 4/8 (50.0) | 0.35 | 4/4 (100.0) | 0/4 (0) | 0.001 |
Female sex | 9/20 (45.0) | 7/12 (58.3) | 2/8 (25.0) | 0.19 | 2/4 (50.0) | 0/4 (0) | 0.42 |
Treatment with ARM/LUM | 5/20 (25.0) | 4/12 (33.3) | 1/8 (12.5) | 0.60 | 0/4 (0) | 1/4 (25.0) | 1.0 |
Treatment with DHA/PPQ | 15/20 (75.0) | 8/12 (75.0) | 7/8 (87.5) | 0.60 | 4/4 (100.0) | 3/4 (75.0) | 1.0 |
Parasitemia† | 0.4 (0.2–1.1) | 0.3 (0.1–0.9) | 0.9 (0.4–1.4) | 0.12 | 1.15 (0.4–1.9) | 0.8 (0.2–1.1) | 0.40 |
Hb d0‡ |
12.5
(11.1–14.0) |
11.3
(10.5–13.5) |
13.1
(12.5–14.1) |
0.11 |
12.7
(12.4–13.8) |
13.7
(12.6–14.6) |
0.30 |
Laboratory follow-up‡ | |||||||
Hb d3 | 12.2 (10.6–13.6) | 11.1 (9.7–12.7) | 13.2 (12.2–14.3) | 0.02 | 12.8 (11.9–13.4) | 14.2 (12.5–14.6) | 0.15 |
Hb d7 | 12.1 (11.1–13.0) | 11.7 (10.5–12.5) | 12.5 (11.9–12.6) | 0.33 | 12.6 (11.8–13.1) | 12.7 (11.5–12.9) | 0.66 |
Hb d14 | 12.0 (10.9–12.6) | 11.7 (10.5–12.6) | 12.2 (11.9–12.6) | 0.33 | 12.5 (12.2–12.8) | 11.9 (10.5–12.5) | 0.11 |
ΔHb d0–d3 | −0.4 (−0.8 to 0.0) | −0.5 (−1.0 to −0.3) | −0.1 (−0.6 to 0.6) | 0.07 | −0.4 (−1.1 to 0.7) | 0.1 (−0.2 to 0.6) | 0.40 |
ΔHb d3–d7 | 0.0 (−0.8 to 0.5) | 0.3 (0.3–0.8) | −0.8 (−1.5 to −0.1) | 0.007 | −0.3 (−0.6 to 0.2) | −1.5 (−1.7 to −1.0) | NA |
ΔHb d7–d14 | 0.1 (−0.5 to 0.5) | 0.3 (0.1–0.5) | −0.4 (−0.9 to 0.1) | 0.04 | 0.0 (−0.4 to 0.4) | −0.8 (−1.2 to −0.3) | NA |
ΔHb d3–d14 | 0.0 (−0.7 to 0.5) | 0.3 (−0.1 to 0.7) | −1.3 (−2.0 to −0.3) | 0.002 | −0.3 (−0.6 to 0.3) | −1.9 (−2.6 to −1.9) | NA |
ΔHb d0–d14 | −0.7 (−1.1 to 0.1) | −0.4 (−0.8 to 0.4) | −1.3 (−2.1 to −0.3) | 0.03 | −0.4 (−1.3 to 0.2) | −1.9 (−2.8 to −1.3) | NA |
LDH d7, U/L | 250 (225–331) | 244 (222–274) | 327 (229–407) | 0.16 | 329 (211–495) | 327 (248–381) | 0.77 |
LDH d14, U/L | 256 (210–283) | 210 (197–247) | 280 (256–365) | 0.006 | 273 (255–394) | 298 (234–365) | 1.0 |
RPI d3 | 0.5 (0.3–0.7) | 0.4 (0.2–0.7) | 0.7 (0.4–0.7) | 0.22 | 0.7 (0.4–0.7) | 0.6 (0.5–0.7) | 1.0 |
RPI d7 | 1.4 (0.9–1.6) | 1.4 (0.9–1.5) | 1.3 (0.8–2.0) | 0.66 | 1.7 (1.2–2.7) | 1.0 (0.4–1.8) | 0.24 |
RPI d14 | 1.4 (1.0–1.8) | 1.1 (1.0–1.6) | 1.9 (1.4–2.6) | 0.015 | 2.5 (1.9–2.9) | 1.5 (1.1–1.9) | 0.04 |
*Values are median (interquartile range) or n/N (%). ACT, artemisinin-based combination therapy; ARM, artemether; d, day; Δ, period between indicated days; DHA, dihydroartemisinin; Hb, hemoglobin; LDH, lactate dehydrogenase; LUM, lumefantrine; NA, not applicable; PPQ, piperaquine; RPI, reticulocyte production index.
†Percentage of erythrocytes infected.
‡Hb levels are in grams/deciliter.